E
Amgen (AMGN) reported on December 3, 2014 that the FDA has approved their Leukemia drug Blincyto (blinatumomab) for the treatment of Philadelphia Chromosome-negative Relapsed or Refractory B-cell precursor Acute Lymphoblastic Leukemia. This disease is an uncommon form of blood cancer where patients had few or no treatment options. With the approval of Blincyto patients now…